Skip to search formSkip to main contentSkip to account menu

cangrelor

Known as: N(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid), [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (1)

AR C69931MX

Broader (3)

Adenosine MonophosphatePlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists
analogs & derivativescangrelor tetrasodium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.
Review
2015
Review
2015
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
2015
2015
Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction.
2013
2013
Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion.
2010
2010
SCH 602539, a Protease-Activated Receptor-1 Antagonist, Inhibits Thrombosis Alone and in Combination With Cangrelor in a Folts Model of Arterial Thrombosis in Cynomolgus Monkeys
Objective—To determine the antithrombotic effects of SCH 602539, an analog of the selective protease-activated receptor (PAR)-1… 
2009
2009
Cangrelor Attenuates Coated-Platelet Formation
P2Y12 inhibitors were introduced clinically as effective inhibitors of adenosine-5′-diphosphate (ADP) mediated platelet… 
Highly Cited
2007
Highly Cited
2007
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect…
2005
2005
Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
Review
2003
Review
2003
ADP receptors--targets for developing antithrombotic agents.
Platelet P2 receptors--P2Y1, P2Y12, and P2X1--constitute the means by which adenine nucleotides can activate platelets… 
Review
2001
Review
2001
Cangrelor AstraZeneca.
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)